The Medical Letter on Drugs and Therapeutics
				
			FROM
ISSUE 1566
    
   			ISSUE 1566
February 25, 2019
                			
                		 Issue 1566
                		- An Epinephrine Prefilled Syringe (Symjepi) for Anaphylaxis
 - Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes
 - Fostamatinib (Tavalisse) for ITP
 - Oxybutynin for Hot Flashes in Women with Breast Cancer
 - Drug Interaction: Opioids and Oral P2Y12 Platelet Inhibitors
 - Elderberry for Influenza
 
					Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
				
				An Epinephrine Prefilled Syringe (Symjepi) for Anaphylaxis
February 25, 2019 (Issue: 1566)
				The FDA has approved a manually
injected, single-dose, prefilled
epinephrine syringe (Symjepi –
Adamis/Sandoz) for emergency
treatment of anaphylaxis. The new
device is approved in 0.3- and
0.15-mg strengths for treatment of
patients...more
        			
        			
					
					
				
        			
				The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
				